Virginia Research Institutions Conducted Over 3,400 Clinical Trials of New Medicines Since 1999

Virginia Research Institutions Conducted Over 3,400 Clinical Trials of New Medicines Since 1999

02.11.13 | By

The message this morning at a Richmond news conference at which a new report "Research in Your Backyard: Pharmaceutical Clinical Trials in Virginia" was released was loud and clear - the 3,412 clinical trials of new medications conducted in the state over the last 13 years by biopharmaceutical companies and their local research collaborators have benefited patients, the state's economy and the advancement of science.

The trials have been conducted for the companies by the health systems at Virginia Commonwealth University and the University of Virginia, the Eastern Virginia Medical School Strelitz Diabetes Center, local hospitals all over the state and the Commonwealth's private clinical research centers.

Today marked the 17th state by state clinical trial report rollout event we've conducted over the last 15 months with governors, state legislators, business leaders, patient advocates, health care provider organizations and academic research collaborators. This morning's conference featured remarks by Virginia Governor Robert McDonnell, the sixth governor to partner with us in releasing clinical trial statistics for their states, and Sheri Lambert, Executive Director of the Virginia Chapter of the Leukemia & Lymphoma Society.

We are not yet prepared to say our mission is accomplished, but we have begun to raise patient awareness of local community clinical trials and their importance to their lives. Medicines have been, and are being, clinically tested in Virginia that could ultimately save and improve lives. And for some chronic disease sufferers still seeking effective treatments, the 267 trials of new medicines still recruiting patients in the state could provide a new therapeutic option to explore and discuss with their doctors.

We have impressed upon a growing number of people in the 17 states we've targeted, including legislators and state policymakers, the fact our biopharmaceutical companies have had a profound impact on patient and economic health in communities all over the country, even if they don't always have a prominent bricks and mortar presence there.

In Richmond this morning, Governor McDonnell applauded the fact 46 percent - over 1,500 - of the 3,412 clinical trials conducted by companies and local research institutions in Virginia targeted the nation's six most debilitating chronic diseases - asthma, heart disease, stroke, cancer, diabetes and mental illnesses.

On the economic front, the governor said clinical trials "support jobs and inject revenue into our communities." The biopharmaceutical sector supports about 76,000 jobs throughout Virginia, he noted.

Lambert emphasized the more than 700 clinical trials of new cancer medicines conducted in the state since 1999 "at a time when cancer strikes tens of thousands of Virginians every year."

"Research in Your Backyard: Pharmaceutical Clinical Trials in Virginia" and the other state by state clinical trial reports can be found at under "Clinical Research and Trials."

Learn more in our press release.

More On PhRMA — powered by PhRMApedia


Cost in Context